BRIEF-Antibe Therapeutics appoints new board member
July 19 (Reuters) - Antibe Therapeutics :
* Anticipates that final results will be available for release by mid-august
* Antibe Therapeutics Announces The Appointment Of New Board Member And Provides Update On Phase 2 Trial Of Atb-346
* Antibe anticipates that final results will be available for release by mid-august
* Elected to pay in-kind all interest due July 15, 2016 under company's 10% senior secured convertible debentures due October 15, 2018
* Aggregate July 15, 2016 interest payment under debentures in amount of $79,521.56 has been added to principal amount of debentures Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
© Thomson Reuters 2017 All rights reserved.